Revlimid

Celgene's Rich Pipeline Offers Growth

Celgene's Rich Pipeline Offers Growth

Seeking Alpha

Celgene's Star Drug Revlimid And Its Competitors

Celgene's Star Drug Revlimid And Its Competitors

Seeking Alpha

Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?

Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?

Motley Fool

Still Revving Up With Revlimid

Still Revving Up With Revlimid

Motley Fool

Revlimid Ramp-Up, New Drug Launches Make Celgene a Buy

Revlimid Ramp-Up, New Drug Launches Make Celgene a Buy

Motley Fool

Celgene's Drug Pipeline News Soothes Investor Worries

Celgene's Drug Pipeline News Soothes Investor Worries

Investors.com

Cramer: What Celgene’s Europe News Means

Cramer: What Celgene’s Europe News Means

CNBC

Celgene down 13% after it pulls Revlimid filing

Celgene down 13% after it pulls Revlimid filing

Marketwatch

Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO

Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO

Yahoo/Business Wire

Expensive Celgene Shares A Better Bet Than Most Biotechs

Expensive Celgene Shares A Better Bet Than Most Biotechs

Seeking Alpha